Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 ALLIANCE PHARMA PLC

17 Apr 2025 13:22

RNS Number : 5088F
Barclays PLC
17 April 2025
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

ALLIANCE PHARMA PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

16 Apr 2025

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

1p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

5,741,923

1.06%

1,956,258

0.36%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

1,063,873

0.20%

5,741,834

1.06%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

6,805,796

1.26%

7,698,092

1.42%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

1p ordinary

Purchase

39,648

0.6420 GBP

1p ordinary

Purchase

14,994

0.6430 GBP

1p ordinary

Sale

43,918

0.6424 GBP

1p ordinary

Sale

35,540

0.6420 GBP

1p ordinary

Sale

14,951

0.6419 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

1p ordinary

SWAP

Decreasing Short

12,863

0.6419 GBP

1p ordinary

SWAP

Decreasing Short

23,698

0.6420 GBP

1p ordinary

SWAP

Decreasing Short

42,076

0.6424 GBP

1p ordinary

SWAP

Increasing Short

25,538

0.6420 GBP

1p ordinary

SWAP

Increasing Short

14,994

0.6430 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

17 Apr 2025

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETIRMBTMTABBBA
Date   Source Headline
23rd Jan 201910:06 amRNSDirector Shareholding
21st Jan 20197:00 amRNSPre-Close Trading Update
2nd Jan 20194:00 pmRNSTotal Voting Rights
31st Dec 20187:00 amRNSBlock Listing Six Monthly Return
17th Dec 20187:00 amRNSAppointment of Non-Executive Directors
6th Dec 20187:00 amRNSTotal Voting Rights
12th Nov 20183:51 pmRNSDirector Share Dealing
7th Nov 20181:35 pmEQSHardman & Co Research: Alliance Pharma (APH): International brands driving performance
5th Oct 201810:25 amRNSGrant of Options to Directors
2nd Oct 20187:00 amRNSXonvea launch in the UK
19th Sep 20187:00 amRNSInterim results
16th Aug 20187:00 amRNSNotice of Results
10th Aug 201810:00 amRNSTotal Voting Rights
1st Aug 20189:56 amEQSHardman & Co Research: Alliance Pharma (APH): 2018: a year of international progress
25th Jul 20187:00 amRNSHalf Year Trading Update
6th Jul 20187:00 amRNSMarketing Authorisation for Diclectin
29th Jun 20187:00 amRNSBlock Listing Six Monthly Return
25th Jun 20189:39 amRNSNotification of Major Holdings
22nd Jun 201811:58 amRNSNotification of Major Holdings
21st Jun 20184:13 pmRNSCompletion of Acquisition and TVR
19th Jun 20182:24 pmRNSResult of Placing
19th Jun 20187:00 amRNSNizoral Acquisition in APAC and Proposed Placing
18th Jun 20185:19 pmRNSNotification of Major Holdings
18th Jun 20185:17 pmRNSNotification of Major Holdings
7th Jun 20187:00 amRNSPositive Opinion on Diclectin
5th Jun 20181:03 pmRNSTotal Voting Rights
30th May 20187:00 amRNSDirectorate Change
24th May 20184:05 pmRNSNotification of Major Holdings
24th May 201811:00 amRNSResult of AGM
24th May 20187:00 amRNSAGM Statement
16th May 20183:05 pmRNSNotification of Major Holdings
2nd May 201812:32 pmRNSTotal Voting Rights
19th Apr 20185:25 pmRNSAnnual Report and AGM Notice
19th Apr 20184:59 pmRNSNotification of Major Holdings
19th Apr 20187:17 amEQSHardman & Co Research: Alliance Pharma (APH): Entering the US market
17th Apr 20187:00 amRNSDisposal of Chinese rights to Forceval
13th Apr 20187:00 amRNSAlliance to present at the UK Investor Show
3rd Apr 20184:09 pmRNSTotal Voting Rights
27th Mar 20187:00 amRNSFull Year Results
6th Mar 20181:48 pmRNSTotal Voting Rights
1st Mar 20187:00 amRNSDirectorate Changes
8th Feb 20185:49 pmRNSTotal Voting Rights
8th Feb 20185:47 pmRNSNotification of Major Holdings
8th Feb 20187:00 amRNSNotification of Preliminary Results
29th Jan 201811:20 amRNSHardman Research: Strong Operational Cashflow
22nd Jan 20187:00 amRNSPre-Close Trading Update
11th Jan 20187:15 amRNSHardman Research: Acquisitions to boost growth
2nd Jan 20182:00 pmRNSTotal Voting Rights
2nd Jan 20187:00 amRNSBlock Listing Six Monthly Return
28th Dec 20177:00 amRNSCompletion of acquisition of Vamousse

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.